The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S48-S51, November 2004

ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER

  • LAURENCE KLOTZ

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Surgery, University of Toronto and Division of Urology, Sunnybrook and Women's College Health Sciences Centre, 2075 Bayview Ave., No. MG 408, Toronto, Ontario M4N 3M5, Canada (telephone: 416-480-4673; FAX: 416-480-6121)
    • Financial interest in and/or other relationship with AstraZeneca, Abbott and Aventis

From the Department of Surgery, University of Toronto and Division of Urology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada

ABSTRACT 

Purpose

This article reviews the data supporting an approach of active surveillance with selective delayed intervention for good risk localized prostate cancer. The challenge is to identify those patients who are not likely to experience significant progression, while offering radical therapy to those who are at risk.

Materials and Methods

A prospective phase 2 study of active surveillance with selective delayed intervention was initiated in 1995. Patients were treated initially with surveillance, while those who had a prostate specific antigen (PSA) doubling time (DT) of 2 years or less, or grade progression on re-biopsy were offered radical intervention. The remainder were closely monitored.

Results

The cohort consisted of 299 patients with good risk prostate cancer or intermediate risk prostate cancer in men older than 70 years. Median PSA DT was 7.0 years and 35% of the men had a PSA DT of greater than 10 years. The majority of patients remain on surveillance. At 8 years overall actuarial survival was 85% and disease specific survival was 99%.

Conclusions

Most men with favorable risk prostate cancer will die of unrelated causes. The approach of active surveillance with selective delayed intervention based on PSA DT represents a practical compromise between radical therapy in all, which results in overtreatment in patients with indolent disease, and watchful waiting with palliative therapy only, which results in under treatment in those with aggressive disease. Results at 8 years are favorable. Longer followup will be required to confirm the safety of this approach in men with long (greater than 15-year) life expectancy.

Key Words::  prostate , prostatic neoplasms , prostate-specific antigen , survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-5347(05)61308-0

doi:10.1097/01.ju.0000141712.79986.77

The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S48-S51, November 2004